share_log
Benzinga ·  May 6 08:05
Krystal Biotech Expects Approximately $150M-$175M Of Adjusted R&D And SG&A Expense In 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment